Skip to main content

Morgan Stanley Reaffirms Their Buy Rating on Legend Biotech (LEGN)

Tipranks - Tipranks - Fri Nov 14, 2025

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Legend Biotech, with a price target of $83.00.

Meet Your ETF AI Analyst

According to TipRanks, Flynn is a 4-star analyst with an average return of 6.6% and a 58.81% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Gilead Sciences, BioNTech SE, and Eli Lilly & Co.

In addition to Morgan Stanley, Legend Biotech also received a Buy from Barclays’s Gena Wang in a report issued today. However, yesterday, William Blair maintained a Hold rating on Legend Biotech (NASDAQ: LEGN).

See today’s best-performing stocks on TipRanks >>

Based on Legend Biotech’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $255.95 million and a GAAP net loss of $125.82 million. In comparison, last year the company earned a revenue of $186.52 million and had a GAAP net loss of $18.2 million

Read More on LEGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).